Eli Lilly and Adocia agree to develop fast-acting insulin

December 19, 2014 8:28 AM

15 0

PARIS (Reuters) - U.S. drugmaker Eli Lilly and French biotech Adocia said on Friday they agreed a worldwide licensing partnership to develop an ultra-rapid insulin to treat patients with Type 1 and Type 2 diabetes.

The fast-acting insulin, called BioChaperone Lispro, is currently in early-stage Phase Ib studies and aims to control glucose levels better during and after meals.

Read more

To category page